Guideline of non-ST segment elevation acute coronary syndrome

Chinese Journal of Cardiology

Volumn 40, Issue 5, 2012, Pages 353-367

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRACTICE GUIDELINE;

ACUTE CORONARY SYNDROME; HUMANS;

EID: 84865018277     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2012.05.001     Document Type: Article

References (98)

1. Dixon S R, Grines C L. The year in interventional cardiology. J Am Coll Cardiol, 2011, 57: 2207-2220.
2. Fox K A, Clayton T C, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol, 2010, 55: 435-445.
3. Wright R S, Anderson J L, Adams C D, et al. 2011 ACCF/AHA focused update of the Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2011, 57: 1920-1959.
4. Hamm C W, Bassand J P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011, 32: 2999-3054.
5. 2007, 35: 295-304.
6. 2010, 38: 675-690.
7. Libby P, Bonow R O. Braunwald's Heart Disease. 8th ed. A textbook of cardiovasucular medicine. Part VII: atherosclerotic cardiovascular disease. Philadelphia: Elsevier Saunders, 2008.
8. Fraker T D Jr, Fihn S D, Gibbons R J, et al. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation, 2007, 116: 2762-2772.
9. Anderson J L, Adams C D, Antman E M, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction). J Am Coll Cardiol, 2007, 50: e1-e157.
10. Okamatsu K, Takano M, Sakai S, et al. Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation, 2004, 109: 465-470.
11. Bonaca M P, Wiviott S D, Braunwald E, et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Circulation, 2012, 125: 577-583.
12. Granger C B, Goldberg R J, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med, 2003, 163: 2345-2353.
13. Yan R T, Yan A T, Mahaffey K W, et al. Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2009, 31; 958-966.
14. Szymański F M, Grabowski M, Filipiak K J, et al. Admission ST-segment elevation in lead aVR as the factor improving complex risk stratification in acute coronary syndromes. Am J Emergency Med, 2008, 26: 408-412.
15. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J, 2010, 31: 2197-2204.
16. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the study group on biomarkers in cardiology of the ESC working group on acute cardiac care [J/OL]. Eur Heart J, 2011 [2011-08-02]. http://eurheartj.oxfordjournals.org/content/early/ 2011/02/02/eurheartj.ehq509.long.
17. Khan S Q, Narayan H, Ng K H, et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci (Lond) , 2009, 117: 31-39.
18. Antman E M, Cohen M, Bernink P J, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000, 284: 835-842.
19. Fox K A, Dabbous O H, Goldberg R J, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ, 2006, 333: 1091-1094.
20. Subherwal S, Bach R G, Chen A Y, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/ AHA guidelines) bleeding score. Circulation, 2009, 119: 1873-1882.
21. Mehran R, Pocock S J, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol, 2010, 55: 2556-2566.
22. Miller C D, Roe M T, Mulgund J, et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med, 2007, 120: 685-692.
23. 2009, 37: 195-209.
24. Dagenais G R, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet, 2006, 368: 581-588.
25. IONA study group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet, 2002, 359: 1269-1275.
26. Antithrombotic trialists' (ATT) collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet, 2009, 373: 1849-1860.
27. Bhatt D L, Cryer B L, Contant C F, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med, 2010, 363: 1909-1917.
28. Wallentin L, Becker R C, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361: 1045-1057.
29. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357: 2001-2015.
30. CURRENT-OASIS 7 Investigators, Mehta S R, Bassand J P, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med, 2010, 363: 930-942.
31. Mega J L, Close S L, Wiviott S D, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet, 2010, 376: 1312-1319.
32. Breet N, van Werkum J, Bouman H, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 2010, 303: 754-762.
33. Kastrati A, Mehilli J, Neumann F J, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA, 2006, 295: 1531-1538.
34. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J, 2010, 31: 35-49.
35. Neumann F J, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA, 2003, 290: 1593-1599.
36. Stone G W, Bertrand M E, Moses J W, et al. Routine upstream initiation vs deferred selective use of glycoprotein II b/III a inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA, 2007, 297: 591-602.
37. Giugliano R P, White J A, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med, 2009, 360: 2176-2190.
38. Berger J S, Frye C B, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol, 2008, 52: 1693-1701.
39. Grines C L, Bonow R O, Casey D E Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 2007, 115: 813-818.
40. Harrington R A, Becker R C, Cannon C P, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest, 2008, 133: 670S-707S.
41. Fifth organization to assess strategies in acute ischemic syndromes investigators, Yusuf S, Mehta S R, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med, 2006, 354: 1464-1476.
42. FUTURA/OASIS-8 trial group, Steg P G, Jolly S S, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA, 2010, 304: 1339-1349.
43. Petersen J L, Mahaffey K W, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA, 2004, 292: 89-96.
44. Stone G W, McLaurin B T, Cox D A, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med, 2006, 355: 2203-2216.
45. Stone G W, White H D, Ohman E M, et al. Acute catheterization and urgent intervention triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the acute catheterization and urgent intervention triage strategy (ACUITY) trial. Lancet, 2007, 369: 907-919.
46. Cohen M, Demers C, Gurfinkel E P, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med, 1997, 337: 447-452.
47. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 2004, 126: 188S-203S.
48. Lip G Y, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary-a consensus document of the European Society of Cardiology working group on thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2010, 31: 1311-1318.
49. APPRAISE steering committee and investigators, Alexander J H, Becker R C, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation, 2009, 119: 2877-2885.
50. Mega J L, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI46): a randomized, double-blind, phase TJ trial. Lancet, 2009, 374: 29-38.
51. Sabatine M S, Antman E M, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomized, double-blind, active-controlled, phase 2 trial. Lancet, 2009, 374: 787-795.
52. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol, 2009, 54: 2157-2163.
53. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation, 2004, 110: 674-678.
54. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol, 2007, 49: 1272-1278.
55. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. J Am Coll Cardiol, 2009, 54: 558-565.
56. Patti G, Chello M, Gatto L, et al. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (atorvastatin for reduction of myocardial damage during angioplasty-cell adhesion molecules) substudy. J Cardiovasc Med, 2010, 11: 795-800.
57. Sever P S, Poulter N R, Dahlof B, et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA). Am J Cardiol, 2005, 96: 39F-44F.
58. Hulten E, Jackson J L, Douglas K, et al. The effect of early, intensive statin therapy on acute coronary syndrome: a metaanalysis of randomized controlled trials. Arch Intern Med, 2006, 166: 1814-1821.
59. Task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J, 2010, 31: 2501-2555.
60. 2012, 40: 271-277.
61. Levine G N, Bates E R, Blankenship J C. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol, 2011, 58: e44-e122.
62. Hillis L D, Smith P K, Anderson J L, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2011, 58: e123-e210.
63. Mehta S R, Granger C B, Boden W E, et al. Early versus delayed invasive intervention in acute coronary syndrome. N Engl J Med, 2009, 360: 2165-2175.
64. Montalescot G, Cayla G, Collet J P, et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA, 2009, 302: 947-954.
65. Sorajja P, Gersh B J, Cox D A, et al. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (acute catheterization and urgent intervention triage strategy) trial. J Am Coll Cardiol, 2010, 55: 1416-1424.
66. Katritsis D G, Siontis G C, Kastrati A, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J, 2010, 32: 32-40.
67. Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (invasive versus conservative treatment in unstable coronary syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol, 2010, 55: 858-864.
68. Jiang M, He B, Zhang Q. Timing of early invasive intervention in patients with moderate to high risk acute coronary syndromes. J Interv Cardiol, 2012, 25: 10-18.
69. Serruys P W, Morice M C, Kappetein A P, et al. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009, 360: 961-972.
70. Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med, 2010, 363: 2310-2319.
71. Greenhalgh J, Hockenhull J, Rao N, et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev, 2010, 5: CD004587.
72. O'Donoghue M, Boden W E, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA, 2008, 300: 71-80.
73. Parikh S V, de Lemos J A, Jessen M E, et al. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients: results from the national cardiovascular data registry ACTION Registry-GWTG (acute coronary treatment and intervention outcomes network registry-get with the guidelines). JACC Cardiovasc Interv, 2010, 3: 419-427.
74. Valgimigli M, Dawkins K, Macaya C, et al. Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial. J Am Coll Cardiol, 2007, 49: 431-441.
75. Mehran R, Rao S V, Bhatt D L, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation, 2011, 123: 2736-2747.
76. Hicks K A, Stockbridge N L, Targum S L, et al. Bleeding academic research consortium consensus report: the food and drug administration perspective. Circulation, 2011, 123: 2664-2665.
77. Steg P G, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the working group on thrombosis of the European Society of Cardiology. Eur Heart J, 2011, 32: 1854-1864.
78. Bassand J P, Afzal R, Eikelboom J, et al. Relationship between baseline hemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J, 2010, 31; 50-58.
79. Hill S R, Carless P A, Henry D A, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev, 2002, 2: CD002042.
80. Zipes D P, Camm A J, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association task force and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death ) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J, 2006, 27: 2099-2140.
81. Schmitt J, Duray G, Gersh B J, et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J, 2009, 30: 1038-1045.
82. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm A J, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010, 31: 2369-2429.
83. Steg P G, Dabbous O H, Feldman L J, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the global registry of acute coronary events (GRACE). Circulation, 2004, 109: 494-499.
84. Dickstein K, Vardas P E, Auricchio A, et al. 2010 focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J, 2010, 31: 2677-2687.
85. Moss A J, Zareba W, Hall W J, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 2002, 346: 877-883.
86. Menzin J, Wygant G, Hauch O, et al. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin, 2008, 24: 461-468.
87. Alexander K P, Newby L K, Cannon C P, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation, 2007, 115: 2549-2569.
88. Mehta S R, Cannon C P, Fox K A, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA, 2005, 293: 2908-2917.
89. Berger J S, Elliott L, Gallup D, et al. Sex differences in mortality following acute coronary syndromes. JAMA, 2009, 302: 874-882.
90. De Caterina R, Madonna R, Sourij H, et al. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J, 2010, 31: 1557-1564.
91. NICE-SUGAR study investigators, Finfer S, Chittock D R, Su S Y, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med, 2009, 360: 1283-1297.
92. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol, 2004, 43: 585-591.
93. Chaitman B R, Hardison R M, Adler D, et al. The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation, 2009, 120: 2529-2540.
94. Stone G W, Kedhi E, Kereiakes D J, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation, 2011, 124: 893-900.
95. Collet J P, Montalescot G, Agnelli G, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein II b/ IH a inhibitors on outcomes. The global registry of acute coronary events. Eur Heart J, 2005, 26: 2285-2293.
96. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA, 2006, 295: 2765-2779.
97. Laskey W K, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol, 2007, 50: 584-590.
98. Szummer K, Lundman P, Jacobson S H, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Circulation, 2009, 120: 851-858.